Drug Search Results
More Filters [+]

Mercaptamine

Alternative Names: mercaptamine, cysteamine, cystagon, cysteamine hydrochloride, rp-103, rp 103, rp103, procysbi, cystaran, cystadrops
Latest Update: 2024-12-10
Latest Update Note: Clinical Trial Update

Product Description

Mercaptamine (cysteamine) bitartrate is used for metabolic conditions (the management of nephropathic cystinosis) and is available in a 50mg or 150mg tablet. (Sourced from: https://www.tga.gov.au/alert/mercaptamine-cysteamine-and-mercaptopurine)

Mechanisms of Action: Autophagy Activator,TG2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Canada | Chile | Colombia | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Japan | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | Switzerland | Turkey | United Arab Emirates | United Kingdom | United States

Approved Indications: Cystinosis | Cystinosis | Cystinosis | Cystinosis

Known Adverse Events: Eye Pain | Headache | Pain Unspecified | Pruritus | Ocular Discomfort | Abdominal Pain | Dizziness | Anorexia | Diarrhea | Enteritis | Gastroenteritis

Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mercaptamine

Countries in Clinic: Australia, Belgium, Canada, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, United Kingdom, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: COVID-19|Cystinosis|Influenza, Human|Pneumonia

Phase 2: Cystic Fibrosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

REMAP-CAP

P3

Recruiting

Influenza, Human|COVID-19|Pneumonia

2026-02-01

SCOB2

P3

Completed

Cystinosis

2022-12-23

68%

jRCT2021200029

P3

Not yet recruiting

Cystinosis

2021-12-31

2015-004986-99

P2

Active, not recruiting

Cystic Fibrosis

2017-07-11

Recent News Events